Amy Theos, MD; Bruce R. Korf, MD, PhD
Potential Financial Conflicts of Interest: Grants received: B.R. Korf (National Institutes of Health, U.S. Army).
Requests for Single Reprints: Bruce R. Korf, MD, PhD, Department of Genetics, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294; e-mail, email@example.com.
Current Author Addresses: Dr. Theos: Department of Dermatology, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294.
Dr. Korf: Department of Genetics, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294.
Theos A., Korf B.; Pathophysiology of Neurofibromatosis Type 1. Ann Intern Med. 2006;144:842-849. doi: 10.7326/0003-4819-144-11-200606060-00010
Download citation file:
Published: Ann Intern Med. 2006;144(11):842-849.
Neurofibromatosis type 1 (NF1) was formerly known as von Recklinghausen disease.
It has autosomal dominant inheritance with complete penetrance, variable expression, and a high rate of new mutation.
It affects approximately 1 in 3500 individuals worldwide.
Diagnostic clinical signs include neurofibromas, café-au-lait macules, skinfold freckling, skeletal dysplasia, Lisch nodules, and optic gliomas.
Persons with NF1 are at increased risk for malignant conditions, especially malignant peripheral nerve sheath tumor (MPNST), leukemia, and rhabdomyosarcoma.
Other complications include cognitive problems and vascular dysplasias.
Molecular genetic testing is available.
Clinical trials of potential therapies for plexiform neurofibromas are under way.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only